Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Far-left party wins Berlin election, pledging to nationalise housing
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
Amphastar Pharma (AMPH) Tops Q3 EPS by 11c
November 8, 2016 4:07 PM ESTAmphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.14, $0.11 better than the analyst estimate of $0.03. Revenue for the quarter came in at $64.2 million versus the consensus estimate of $65.12 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More